Organon to acquire Dermavant for $1.2bn, expanding its presence in immuno-dermatology
Organon, a global healthcare company focused on women’s health, has announced a definitive agreement to acquire Dermavant Sciences Ltd., a Roivant company specialising in immuno-dermatology, ... Read More
Roivant Sciences, Pfizer create new business for inflammatory disease drug
Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel ... Read More
Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition
Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in a deal that values the Swiss biopharma ... Read More
Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss ... Read More
Roivant Sciences launches Respivant Sciences to advance treatments for respiratory diseases
Roivant Sciences has launched a new biopharma company, Respivant Sciences, to focus on cutting-edge treatments for severe respiratory conditions. The newly established Respivant Sciences will ... Read More